> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Inovio Puts Preliminary Cash And Investment Balance At About $48.4 Million
- URL: https://www.bullished.co/inovio-puts-preliminary-cash-and-investment-balance-at-about-48-4-million-f435474a/
- Published: 2026-11-06T14:10:59.000Z
- Updated: 2026-11-06T14:10:59.000Z
- Description: The biotech’s medicines remain in development, and its quarter-end balance is subject to completion of financial closing procedures.
- Author: Matteo Parrino
- Tags: SEC Filings, INO, Industry: Healthcare

[Inovio Pharmaceuticals](https://www.bullished.co/tag/ino/), which develops DNA medicines for HPV-related diseases, cancer and infectious diseases, estimates it held [approximately $48.4 million](https://www.sec.gov/Archives/edgar/data/0001055726/000119312526449853/d141738d8k.htm?ref=bullished.co) in cash, cash equivalents and short-term investments on September 30, 2026\. The company gave the preliminary, unaudited estimate in an SEC filing Thursday, with the balance still subject to its quarter-end financial closing work.

## A Balance Still Being Finalized

The estimate combines cash with cash equivalents and short-term investments; it is a quarter-end asset balance, rather than a measure of revenue or earnings. Management prepared the figures and is responsible for them.

Inovio cautioned that the final quarterly figures [could differ materially](https://www.sec.gov/Archives/edgar/data/0001055726/000119312526449853/d141738d8k.htm?ref=bullished.co) as it completes its accounting work. Changes to assumptions and estimates, internal-control reviews and other closing procedures could affect the results.

Ernst & Young has provided no assurance on the preliminary numbers, the company said. Inovio also described the update as a limited financial estimate rather than comprehensive results for the third quarter.

## DNA Medicines Before Product Sales

The cash balance sits alongside a business still developing its medicines. In its annual report for the year ended December 31, 2025, Inovio said all its candidates remained in research and development and that it had earned no revenue from selling products. Its revenue sources were licensing fees, milestone payments and collaborative research agreements and contracts.

Inovio’s lead candidate, INO-3107, targets recurrent respiratory papillomatosis, a rare condition that produces tumors in the airway. Other candidates address throat cancer and other cancers.

The company’s approach uses plasmids—small loops of DNA—to tell cells to produce particular proteins. Its CELLECTRA delivery devices use short electrical pulses to move those medicines into cells.

The annual report said Inovio’s DNA medicines had been administered more than 19,000 times to nearly 6,000 participants to date. Those administrations describe the research program’s reach, while the company’s candidates remain in development.

For Inovio, the approximately $48.4 million is a preliminary balance alongside an unfinished drug-development program—not a finalized quarterly financial result.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — INOVIO PHARMACEUTICALS, INC. (INO)](https://www.sec.gov/Archives/edgar/data/0001055726/000119312526449853/d141738d8k.htm?ref=bullished.co) — SEC EDGAR

### More on Inovio Pharmaceuticals

- [Inovio Wins FDA Accelerated Approval For Voceryq, Its First Product, After 7 Of 26 Patients Needed No Surgery](https://www.bullished.co/inovio-wins-fda-accelerated-approval-for-voceryq-its-first-product-after-7-of-26-patients-b2c916f0/)

[All Inovio Pharmaceuticals (INO) coverage →](https://www.bullished.co/tag/ino/)